Differential response to treatment with the bis(ethyl)polyamine analogues between human small cell lung carcinoma and undifferentiated large cell lung carcinoma in culture - PubMed

Affiliations

• PMID: 2535963

Differential response to treatment with the bis(ethyl)polyamine analogues between human small cell lung carcinoma and undifferentiated large cell lung carcinoma in culture

R A Casero Jr et al. Cancer Res. 1989.

Abstract

We have compared the effects of treatment with each of three bis(ethyl)polyamine analogues on a human small cell lung carcinoma (SCLC) line, NCI H82, and a non-small cell line, NCI H157, an undifferentiated large cell lung carcinoma. The bis(ethyl)polyamines have been shown to interfere with polyamine metabolism, presumably by regulation of the polyamine biosynthetic pathway in a manner similar to the natural polyamines, in contrast to direct inhibition of specific enzymes, such as ornithine decarboxylase. Each of these compounds was found to be relatively inactive in reducing growth rate, polyamine levels, or polyamine biosynthetic enzyme activity in the SCLC cells, a line which we have previously shown to be particularly sensitive to inhibition of polyamine biosynthesis by the direct ornithine decarboxylase inhibitor difluoromethylornithine. By contrast, each of the bis(ethyl)polyamines tested was found to be markedly cytotoxic (at concentrations of only 10 microM) to the non-SCLC line, NCI H157. Interestingly, the non-SCLC line has previously been demonstrated to be resistant to polyamine depletion by difluoromethylornithine. For each bis(ethyl)polyamine, cytotoxicity was accompanied by nearly complete depletion of all intracellular polyamines and a decrease in ornithine decarboxylase activity to undetectable levels. The current study emphasizes the phenotypic variability which can exist in response to inhibitors of polyamine biosynthesis and suggests a class of agents which may have clinical utility against the treatment-resistant non-SCLC lung cancers.

Similar articles

• Differential induction of spermidine/spermine N1-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues.

  Casero RA Jr, Celano P, Ervin SJ, Porter CW, Bergeron RJ, Libby PR. Casero RA Jr, et al. Cancer Res. 1989 Jul 15;49(14):3829-33. Cancer Res. 1989. PMID: 2544259

• Polyamine analogues - an update.

  Wallace HM, Niiranen K. Wallace HM, et al. Amino Acids. 2007 Aug;33(2):261-5. doi: 10.1007/s00726-007-0534-z. Epub 2007 Apr 19. Amino Acids. 2007. PMID: 17443267 Review.

• Polyamines as targets for therapeutic intervention.

  Marton LJ, Pegg AE. Marton LJ, et al. Annu Rev Pharmacol Toxicol. 1995;35:55-91. doi: 10.1146/annurev.pa.35.040195.000415. Annu Rev Pharmacol Toxicol. 1995. PMID: 7598507 Review.

Cited by

• Investigations of the mechanism by which mammalian cell growth is inhibited by N1N12-bis(ethyl)spermine.

  Albanese L, Bergeron RJ, Pegg AE. Albanese L, et al. Biochem J. 1993 Apr 1;291 ( Pt 1)(Pt 1):131-7. doi: 10.1042/bj2910131. Biochem J. 1993. PMID: 8471032 Free PMC article.

• Post-transcriptional regulation of the content of spermidine/spermine N1-acetyltransferase by N1N12-bis(ethyl)spermine.

  Parry L, Balaña Fouce R, Pegg AE. Parry L, et al. Biochem J. 1995 Jan 15;305 ( Pt 2)(Pt 2):451-8. doi: 10.1042/bj3050451. Biochem J. 1995. PMID: 7832759 Free PMC article.

• Two polyamine analogs (BE-4-4-4 and BE-4-4-4-4) directly affect growth, survival, and cell cycle progression in two human brain tumor cell lines.

  Bergeron CJ, Basu HS, Marton LJ, Deen DF, Pellarin M, Feuerstein BG. Bergeron CJ, et al. Cancer Chemother Pharmacol. 1995;36(5):411-7. doi: 10.1007/BF00686190. Cancer Chemother Pharmacol. 1995. PMID: 7634383

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal